Mechanism for human-specific hepatotoxicity and development of prediction system

人类特异性肝毒性机制及预测系统开发

基本信息

  • 批准号:
    17390039
  • 负责人:
  • 金额:
    $ 9.66万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    2005
  • 资助国家:
    日本
  • 起止时间:
    2005 至 2006
  • 项目状态:
    已结题

项目摘要

To identify the mechanism for human-specific hepatotoxicity and develop the prediction system, flutamide and bile acid models were used. The metabolism of flutamide was analyzed using human CYP expressed microsomes. FLU-1-N-OH (N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine) which is a candidate of metabolic intermediate for flutamide-induced hepatotoxicity was produced from FLU-1 by human CYP3A4. In mice, FLU-1 N-hydroxylation was mainly catalyzed by Cyp isoforms different from Cyp3a isoforms. Furthermore, mouse hepatotoxicity model was established by co-treatment with FLU-1 and TCPOBOP. We are analyzing the mechanism for fulutamide-induced hepatotoxicity using the mouse model.To analyze the mechamism for hepatotoxicity through the interaction between endogenous compound (bile acid) and drug, C57/BL6 male mice were treated with cholic acid and ampicillin. Cholic acid (CA) or ampicillin treatment did not cause hepatotoxicity, but CA and ampicillin co-treatment cause severe hepatotoxicity in the mice. These results suggest the presence of the interaction between CA and ampicilin involved in hepatotoxicity. On the other hand, cholic acid treatment causes hepatotoxicity in fornesoid X receptor (FXR)-null mice. After co-treatment with 1.25% cholesterol (Chol), serum ALT and ALP activities were significantly decreased in FXR-null mice fed a 0.5% cholic acid diet, as compared to those of the CA diet controls. Clear decreases were observed on ileal bile acid absorption capacity estimated by a in situ loop method and contents of ileal Asbt protein in FXR-null mice fed the CA plus Chol diet. These results indicate a protective role of cholesterol against bile acid-induced toxicity and also suggest the presence of an FXR-independent suppressive mechanism of ileal bile acid absorption.
为了确定人类特异性肝毒性的机制并建立预测系统,使用了氟他胺和胆汁酸模型。利用人CYP表达微粒体分析氟他胺的代谢。flu1 -1-N- oh (N-[4-硝基-3-(三氟甲基)苯基]羟胺)是氟酰胺引起肝毒性的候选代谢中间体。在小鼠中,flu1 n -羟基化主要由不同于Cyp3a亚型的Cyp亚型催化。建立小鼠肝毒性模型,并与FLU-1和TCPOBOP联合治疗。我们正在用小鼠模型分析氟脲引起肝毒性的机制。为了分析内源性化合物(胆汁酸)与药物相互作用对C57/BL6雄性小鼠的肝毒性作用机制,采用胆酸和氨苄西林联合治疗。胆酸(CA)和氨苄西林均未引起肝毒性,但胆酸和氨苄西林联合用药可引起小鼠严重的肝毒性。这些结果表明CA和氨苄西林之间的相互作用参与了肝毒性。另一方面,胆酸处理引起fornesoid X受体(FXR)缺失小鼠的肝毒性。在与1.25%胆固醇(Chol)共同处理后,与CA日粮对照组相比,饲喂0.5%胆酸日粮的无fxr小鼠血清ALT和ALP活性显著降低。用原位环法测定的回肠胆汁酸吸收能力和饲喂CA + Chol的FXR-null小鼠回肠Asbt蛋白含量明显下降。这些结果表明胆固醇对胆汁酸诱导的毒性具有保护作用,也表明存在不依赖于fxr的回肠胆汁酸吸收抑制机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Role for enhanced fecal excretion of bile acid in hydroxysteroid sulfotransferase-mediated protection against lithocholic acid-induced liver toxicity
增强胆汁酸粪便排泄在羟基类固醇磺基转移酶介导的针对石胆酸诱导的肝毒性的保护中的作用
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    M.Miyata;H.Watase;W.Hori;M.Shimada;K.Nagata;F.J.Gonzalez;Y.Yamazoe
  • 通讯作者:
    Y.Yamazoe
Role for enhanced tecal excretion of bile acid in hydroxysteroid sulfotransferase-mediated protection against lithocholic acid-induced liver toxicity
增强胆汁酸的 tecal 排泄在羟基类固醇磺基转移酶介导的针对石胆酸诱导的肝毒性的保护中的作用
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    M.Miyata;H.Watase;W.Hori;M.Shimada;K.Nagata;F.J.Gonzalez;Y.Yamazoe
  • 通讯作者:
    Y.Yamazoe
Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients
  • DOI:
    10.1124/dmd.105.008623
  • 发表时间:
    2006-05-01
  • 期刊:
  • 影响因子:
    3.9
  • 作者:
    Goda, R;Nagai, D;Yamazoe, Y
  • 通讯作者:
    Yamazoe, Y
Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase
  • DOI:
    10.2133/dmpk.21.315
  • 发表时间:
    2006-01-01
  • 期刊:
  • 影响因子:
    2.1
  • 作者:
    Miyata, Masaaki;Matsuda, Yoshiki;Yamazoe, Yasushi
  • 通讯作者:
    Yamazoe, Yasushi
Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyllhydroxylamine, in human liver microsomes and urine of prostate cancer patients
在人肝微粒体和前列腺癌患者尿液中检测氟他胺的新 N-氧化代谢物 N-[4-硝基-3-(三氟甲基)苯基羟胺
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    M.Miyata;Y.Matsuda;H.Tsuchiya;H.Kitada;T.Akase;M.Shimada;K.Nagata;F.J.Gonzalez;Y.Yamazoe;R.Goda
  • 通讯作者:
    R.Goda
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YAMAZOE Yasushi其他文献

YAMAZOE Yasushi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YAMAZOE Yasushi', 18)}}的其他基金

CYP3A4 induction-associated dyslipidemia : a new risk factor for lifestyle disease
CYP3A4诱导相关的血脂异常:生活方式病的新危险因素
  • 批准号:
    22659028
  • 财政年份:
    2010
  • 资助金额:
    $ 9.66万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Regulation of hepatic lipid metabolism through ileal bile acid-FGF signaling
通过回肠胆汁酸-FGF信号调节肝脏脂质代谢
  • 批准号:
    21390039
  • 财政年份:
    2009
  • 资助金额:
    $ 9.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mechanisms for delayed organ toxicity induced by drug and prediction system using comprehensive analysis
药物迟发性器官毒性机制及综合分析预测系统
  • 批准号:
    19390037
  • 财政年份:
    2007
  • 资助金额:
    $ 9.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Bile acids, key compounds for the mechanistic analyses of hepatotoxicity, and nuclear receptor interaction
胆汁酸,肝毒性机制分析和核受体相互作用的关键化合物
  • 批准号:
    15390043
  • 财政年份:
    2003
  • 资助金额:
    $ 9.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Human characteristic mechanism of enzyme induction and the prediction
人体特有的酶诱导机制及预测
  • 批准号:
    13470510
  • 财政年份:
    2001
  • 资助金额:
    $ 9.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Grapefruit juice-drug interaction and the prediction
葡萄柚汁与药物的相互作用及预测
  • 批准号:
    12557225
  • 财政年份:
    2000
  • 资助金额:
    $ 9.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Role of intestinal oxidative metabolism on first pass effect
肠道氧化代谢对首过效应的作用
  • 批准号:
    09470496
  • 财政年份:
    1997
  • 资助金额:
    $ 9.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of as table expression system for human drug metabolizing enzymes
人药物代谢酶as表表达系统的开发
  • 批准号:
    07557149
  • 财政年份:
    1995
  • 资助金额:
    $ 9.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Analysis of mechanism of neonatal imprinting of drug-metabolizing enzymes of rat liver
大鼠肝脏药物代谢酶新生期印记机制分析
  • 批准号:
    60480130
  • 财政年份:
    1985
  • 资助金额:
    $ 9.66万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)

相似海外基金

Targeting the CCR6-CCL20 pathway for treatment of psoriatic joint and entheseal inflammation
靶向 CCR6-CCL20 通路治疗银屑病关节和附着点炎症
  • 批准号:
    10699251
  • 财政年份:
    2023
  • 资助金额:
    $ 9.66万
  • 项目类别:
Bile acid-dependent T cell regulation in the intestine
肠道内胆汁酸依赖性 T 细胞调节
  • 批准号:
    10767546
  • 财政年份:
    2023
  • 资助金额:
    $ 9.66万
  • 项目类别:
Bacterial metabolism of catechol-O-methyltransferase inhibitors alters drug efficacy and toxicity
儿茶酚-O-甲基转移酶抑制剂的细菌代谢改变药物疗效和毒性
  • 批准号:
    10606184
  • 财政年份:
    2023
  • 资助金额:
    $ 9.66万
  • 项目类别:
Engineering the Next Generation of Safer Hsp90 Inhibitors
设计下一代更安全的 Hsp90 抑制剂
  • 批准号:
    10587304
  • 财政年份:
    2023
  • 资助金额:
    $ 9.66万
  • 项目类别:
Targeting Ischemia-Induced Autophagy Dependence in hepatocellular Carcinoma through Image-guided Locoregional Therapy
通过图像引导局部治疗靶向肝细胞癌中缺血诱导的自噬依赖性
  • 批准号:
    10585078
  • 财政年份:
    2023
  • 资助金额:
    $ 9.66万
  • 项目类别:
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 9.66万
  • 项目类别:
Multicellular Organotypic Mouse Model of Alcoholic Liver Disease
酒精性肝病的多细胞器官型小鼠模型
  • 批准号:
    10667672
  • 财政年份:
    2023
  • 资助金额:
    $ 9.66万
  • 项目类别:
Circadian and mitochondrial dysfunction in alcohol-related liver disease
酒精相关性肝病中的昼夜节律和线粒体功能障碍
  • 批准号:
    10667861
  • 财政年份:
    2023
  • 资助金额:
    $ 9.66万
  • 项目类别:
Perfluoroalkyl substances and non-alcoholic fatty liver disease in children: Leveraging magnetic resonance imaging to unravel potential mechanisms and exposure mixture effects
全氟烷基物质与儿童非酒精性脂肪肝:利用磁共振成像揭示潜在机制和暴露混合物效应
  • 批准号:
    10646759
  • 财政年份:
    2023
  • 资助金额:
    $ 9.66万
  • 项目类别:
Genomic and environmental drivers of HCC in Non-Hispanic Blacks: Nature and nurture
非西班牙裔黑人 HCC 的基因组和环境驱动因素:先天和后天
  • 批准号:
    10856546
  • 财政年份:
    2023
  • 资助金额:
    $ 9.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了